Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2×2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment

International Journal of Stroke

Volumn 10, Issue 5, 2015, Pages 778-788

  Huang, Yining ^a   Sharma, Vijay K ^b   Robinson, Thompson ^c   Lindley, Richard I ^d   Chen, Xiaoying ^d   Kim, Jong Sung ^e   Lavados, Pablo ^f,g   Olavarría, Verónica ^f   Arima, Hisatomi ^d   Fuentes, Sully ^d   Nguyen, Huy Thang ^h   Lee, Tsong Hai ⁱ   Parsons, Mark W ^j   Levi, Christopher ^j   Demchuk, Andrew M ^k   Bath, Philip M W ^l   Broderick, Joseph P ^m   Donnan, Geoffrey A ⁿ   Martins, Sheila ^o   Pontes Neto, Octavio M ^p   Silva, Federico ^q   Pandian, Jeyaraj ^r   Ricci, Stefano ^s   Stapf, Christian ^t   Woodward, Mark ^d   Wang, Jiguang ^u   Chalmers, John ^d   Anderson, Craig S ^d   more..

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e University of Ulsan   (South Korea)

^f UNIVERSIDAD DEL DESARROLLO   (Chile)

^g UNIVERSITY OF CHILE   (Chile)

^h People's Hospital 115   (Viet Nam)

ⁱ CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^j UNIVERSITY OF NEWCASTLE   (Australia)

^k UNIVERSITY OF CALGARY   (Canada)

^l UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^m UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

ⁿ FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^o HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^p UNIVERSITY OF SÃO PAULO   (Brazil)

^q Instituto de Investigaciones   (Colombia)

^r CHRISTIAN MEDICAL COLLEGE   (India)

^s Emergency Department   (Italy)

^t HÔPITAL LARIBOISIÈRE   (France)

^u SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

more..

Author keywords

Acute ischaemic stroke; Alteplase; Dose; Hypertension; Rt PA; Thrombolysis

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; EARLY NEUROLOGICAL DETERIORATION; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HEALTH CARE COST; HUMAN; LENGTH OF STAY; LOW DRUG DOSE; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT RISK; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RESIDENTIAL CARE; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; CLINICAL TRIAL; COMPLICATION; INTERNATIONAL COOPERATION; STROKE; TREATMENT OUTCOME;

BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTERNATIONAL COOPERATION; MALE; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84931572199     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12486     Document Type: Article

References (42)

1. Emberson J, Lees KR, Lyden P etal. Effect of treatment delay, age and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384:1929-1935.
2. Wardlaw JM, Murray V, Berge E etal. Recombiant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379:2364-2372.
3. The national institute of disorders and stroke rt-PA stroke study group: tissue Plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-1587.
4. Brott TG, Haley EC Jr, Levy DE etal. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23:632-640.
5. Haley EC Jr, Levy DE, Brott TG etal. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23:641-645.
6. Haley EC Jr, Brott TG, Sheppard GL etal. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke: the TPA Bridging Study Group. Stroke 1993; 24:1000-1004.
7. Hacke W, Donnan G, Fieschi C etal. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363:768-774.
8. Hacke W, Kaste M, Bluhmki E etal. Thrombolysis with alteplase 3 to 4·5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317-1329.
9. Jauch EC, Saver JL, Adams HP etal. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44:870-947.
10. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004; 61:1066-1070.
11. Mori E, Yoneda Y, Tabuchi M etal. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42:976-982.
12. Yamaguchi T, Kikuchi H, Hayakawa H. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute ischaemic stroke; in Yamaguchi T, Mori E, Minematsu K, Zoppo GD (eds): Thrombolytic Therapy in Acute Ischaemic Stroke III. Tokyo, Springer-Verlag, 1995:223-229.
13. Ueshima S, Matsuo O. The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians. Thromb Haemost 2002; 87:544-546.
14. Iso H, Folsom AR, Koike KA etal. Antigens of tissue plasminogen activator and plasminogen activator inhibitor 1: correlates in nonsmoking Japanese and Caucasian men and women. Thromb Haemost 1993; 70:475-480.
15. Murata M. Genetic polymorphisms associated with thrombotic disorders in the Japanese population Fibrinolysis Proteolysis 2000; 14:155-164.
16. Shaw GJ, Meunier JM, Lindsell CJ, Pancioli AM, Holland CK. Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study. Thromb Res 2010; 126:e305-311.
17. Yamaguchi T, Mori E, Minematsu K etal. Alteplase at 0·6mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37:1810-1815.
18. Toyoda K, Koga M, Naganuma M etal. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. Stroke 2009; 40:3591-3595.
19. Nakagawara J, Minematsu K, Okada Y etal. Thrombolysis with 0·6mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010; 41:1984-1989.
20. Pandian JD, Srikanth V, Read SJ, Thrift AG. Poverty and stroke in India: a time to act. Stroke 2007; 38:3063-3069.
21. Sharma VK, Ng KW, Venketasubramanian N etal. Current status of intravenous thrombolysis for acute ischemic stroke in Asia. Int J Stroke 2011; 6:523-530.
22. Wardlaw JM, Koumellis P, Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database Syst Rev 2013; (5):Art. No.: CD000514. doi: 10.1002/14651858.CD000514.pub3.
23. Qureshi AI, Ezzeddine MA, Nasar A etal. Prevalence of elevated blood pressure in 563, 704 adult patients with stroke presenting to the ED in the United States. Am J Emerg Med 2007; 25:32-38.
24. Geeganage CM, Bath PM. Relationship between therapeutic changes in blood pressure and outcomes in acute stroke: a metaregression. Hypertension 2009; 54:775-781.
25. Qureshi AI. Acute hypertensive response in patients with stroke: pathophysiology and management. Circulation 2008; 118:176-187.
26. Tikhonoff V, Zhang H, Richart T, Staessen JA. Blood pressure as a prognostic factor after acute stroke. Lancet Neurol 2009; 8:938-948.
27. Elewa HF, Kozak A, Johnson MH, Ergul A, Fagan SC. Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection. J Hypertens 2007; 25:855-859.
28. Brott T, Lu M, Kothari R etal. Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke 1998; 29:1504-1509.
29. Tsivgoulis G, Frey JL, Flaster M etal. Pre-tissue plasminogen activator blood pressure levels and risk of symptomatic intracerebral hemorrhage. Stroke 2009; 40:3631-3634.
30. Wahlgren N, Ahmed N, Eriksson N etal. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST). Stroke 2008; 39:3316-3322.
31. Ahmed N, Wahlgren N, Brainin M etal. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke 2009; 40:2442-2449.
32. Sandset EC, Bath PM, Boysen G etal. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011; 377:741-750.
33. TheENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. Lancet 2015; 385:617-628.
34. Anderson CS, Heeley E, Huang Y etal. Rapid blood pressure lowering in acute intracerebral hemorrhage. New Engl J Med 2013; 368:2355-2365.
35. Bamford JM, Sandercock PA, Warlow CP, Slattery J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1989; 20:828.
36. Brott T, Adams HP Jr, Olinger CP etal. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20:864-870.
37. Bath PMW, Lees KR, Schellinger PD etal. on behalf of the European Stroke Organisation Outcomes Working Group. Statistical analysis of the primary outcome in acute stroke trials. Stroke 2012; 43:1171-1178.
38. Howard G, Waller JL, Voeks JH etal. A simple, assumption-free, and clinically interpretable approach for analysis of modified Rankin outcomes. Stroke 2012; 43:664-669.
39. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33:337-343.
40. Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2014; (7):Art. No.: CD000213. doi: 10.1002/14651858.CD000213.pub3.
41. Georgladis AL, Memon A, Shah QA etal. Comparison of partial (·6mg/kg) versus full-dose (·9mg/kg) intravenous recombinant tissue plasminogen activator followed by endovascular treatment for acute ischemic stroke: a meta-analysis. J Neuroimaging 2011; 21:113-120.
42. Menon BK, Saver JL, Prabhakaran S etal. Rick score for intracranial haemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke 2012; 43:2293-2299.